Tender notice
NHS Pharmaceuticals 2017_2
Notice details
- Published
- Category
- goods
- Buyer region
- North West
- Source
- View official notice
Public buyer
Public buyer
NHS EnglandTender value£45,850,500
- Planned startAs published in the notice
- Planned endAs published in the notice
Work description
NHS Pharmaceuticals 2017_2. Period of framework agreement: The total maximum duration of the framework agreement to be no more than 36 months. Potential periods of call-offs under the framework agreement: CESW regions: 1.8.2018 to 28.2.2019 (7 months). NWLN regions: 1.8.2018 to 31.7.2019 (12 months). LSNE regions: 1.8.2018 to 31.1.2020 (18 months). Products on the framework include (but are not necessarily limited to): Abacavir, Abiraterone, Anidulafungin, Atovaquone, Bosentan, Ciclesonide, Drospirenone/Ethinylestradiol, Enfurvitide, Ethinylestradiol/Norelgestromin, Exenatide, Ezetimibe, Iloprost, Ivabradine, Mycophenolic acid, Nitisinone, Olopatadine, Oseltamivir, Parecoxib, Pegfilgrastim, Pegvisomant, Pregabalin, Tadalafil, Tenofovir, Tigecycline, Valproic acid, Velaglucerase. Details of regions, presentation sizes and volumes are within the tender document set.
Additional information: The procurement exercise is being conducted on the NHS England eTendering portal at www.nhsengland.bravosolution.co.uk the project code is tender_1479 and the ITT code is itt_422. This is where the ITO documents are available.